scheduleThe Daily SynthesisToday

A large real-world study of UK health records linked semaglutide, the ingredient in Ozempic and Wegovy, to far fewer asthma attacks and COPD flare-ups, but the benefit did not show up for the other GLP-1 drugs tested

A diabetes and weight-loss drug was tied to nearly 40 percent fewer asthma attacks, and it was one drug in the class, not all of them

A UK real-world study presented at the 2026 ERS Congress tied semaglutide to nearly 40 percent fewer asthma attacks and 20 percent fewer COPD flare-ups. Here is what it means, and its limits.

scienceVital Care Express Research

Read Full Report arrow_forward

Recent Articles

View all articles arrow_forward

Vosoritide Increases Growth Rate in Phase 3 Hypochondroplasia Study

Endocrinology

Phase 3 Trial Shows Vosoritide Accelerates Growth in Hypochondroplasia

A phase 3 trial published in NEJM Evidence shows daily vosoritide injections increased annualized growth velocity by 2.33 cm/year in hypochondroplasia.

Phase 2 Mosliciguat Trial Yields 56.3 Percent PVR Reduction in PH-ILD, Phase 3 PHrontier Begins

Pulmonology

Mosliciguat Shows 56.3 Percent PVR Cut in Phase 2 PH-ILD Study

Roivant reports Phase 2 PHocus results for mosliciguat in PH-ILD, showing a 56.3% PVR reduction, and launches the Phase 3 PHrontier trial.

Novo Nordisk STEP Young Trial Shows 40.4% of Children Moved Below Obesity Threshold

Pediatrics

Semaglutide Helps 40.4% of Pediatric Trial Group Fall Below Obesity Cutoff

Novo Nordisk phase 3 STEP Young trial shows 40.4 percent of children taking semaglutide moved below the obesity BMI threshold after 68 weeks.

Israeli Researchers Develop $60 Blood Test Detecting Stage 2-4 Lung Cancer with 93% Accuracy

Oncology

Israeli Researchers Develop $60 Blood Test for Stage 2-4 Lung Cancer

A new Israeli liquid biopsy test costing $60 detected stage 2-4 lung cancer with 93% sensitivity, bypassing expensive DNA sequencing.

Genetics of Personality Tied to Major Life Outcomes in 46-Cohort Global Study

Genomics

Genetics of Personality Tied to Major Life Outcomes in Global Study

An international study of 46 cohorts identifies over 1200 genetic variants linked to Big Five personality traits, health, income, and lifestyle habits.

A once-daily pill cut MS relapses in two big trials, but Novartis is holding the exact numbers back

Neurology

Novartis says its oral BTK inhibitor remibrutinib beat a standard MS pill on relapses and showed no liver safety signal in the Phase III REMODEL trials, with full data still to come

Novartis's oral BTK inhibitor remibrutinib met its primary goal in two Phase III MS trials, cutting relapse rates versus teriflunomide with no liver safety signal. The exact effect sizes are not out yet.